Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
Annual report ‘Tuberculosis in the Netherlands’ for 2021: slight increase in number of TB patients In 2021, the number of tuberculosis (TB) patients in the Netherlands rose slightly compared to the preceding year: up to 680 TB patients from 622 in 2020. However, the 2021 number was lower than the number for 2019 (754 patients).
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Target group-oriented information more effective in the prevention of skin cancer Avoid sunburn. This is the main advice for the prevention of skin cancer. Targeted information is needed to ensure that people adapt their behaviour accordingly. In places where people are exposed to the sun, for example, or for certain groups of peo
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
Number of tuberculosis patients in the Netherlands increased slightly in 2021 compared to 2020 The number of people with tuberculosis (TB) in the Netherlands increased slightly in 2021, reaching 680. This figure is 9% higher than it was in 2020 (622 patients).
RIVM expands HPV vaccination programme: girls and boys protected from six types of cancer with one vaccine Now not only girls, but also boys will have the opportunity to protect themselves from cancer caused by HPV.
RIVM to play greater role in tuberculosis control The Committee for Practical Tuberculosis Control (CPT) will be transferred per 1 January 2022 to the National Institute for Public Health and the Environment (RIVM) after a period of 70 years with KNCV Tuberculosis Foundation.
New WHO Collaborating Centre hosted by RIVM combines laboratory preparedness and biorisk RIVM has been designated WHO Collaborating Centre for Laboratory Preparedness and Response for High Threat Pathogens and Biorisk by the World Health Organization (WHO).